• Overview
    • Company
      • Company Profile
      • Management
      • Our History
      • Great Place to Work
    • Science
      • Scientific Approach
      • Innate Immunity & NK Cells
      • Antibody Formats
      • Anket: Our NK Cell Engager Platform
      • Publications
    • Products
      • Pipeline Overview
      • Clinical Trials
      • Lacutamab
      • Monalizumab
      • Avdoralimab
      • IPH5201
      • IPH5301
      • IPH6101
      • IPH62
    • Partnering
    • Investors
      • Overview
      • News
      • Events
      • Stock Info
        • Share Information
        • Stock Quote & Chart
        • Analyst Coverage
      • Financials & Regulatory Information
        • Financial Reports
        • SEC Filings
        • Number of Shares and Voting Rights
        • Articles of Association
        • Share Repurchase Liquidity Agreement
        • Prospectus Related to Public Offering
        • Appraiser Reports
        • Regulated Agreements
      • General Shareholders' Meeting
      • Governance
        • Corporate Governance
        • Management Team
      • Resources
        • Investor Email Alerts
    • Media
      • Media Hub
      • All Press Releases
      • Media Center
    • Careers
Skip to main content
Français
Innate Pharma logo

Share Repurchase Liquidity Agreement

  • Overview
    • Company
      • Company Profile
      • Management
      • Our History
      • Great Place to Work
    • Science
      • Scientific Approach
      • Innate Immunity & NK Cells
      • Antibody Formats
      • Anket: Our NK Cell Engager Platform
      • Publications
    • Products
      • Pipeline Overview
      • Clinical Trials
      • Lacutamab
      • Monalizumab
      • Avdoralimab
      • IPH5201
      • IPH5301
      • IPH6101
      • IPH62
    • Partnering
    • Investors
      • Overview
      • News
      • Events
      • Stock Info
        • Share Information
        • Stock Quote & Chart
        • Analyst Coverage
      • Financials & Regulatory Information
        • Financial Reports
        • SEC Filings
        • Number of Shares and Voting Rights
        • Articles of Association
        • Share Repurchase Liquidity Agreement
        • Prospectus Related to Public Offering
        • Appraiser Reports
        • Regulated Agreements
      • General Shareholders' Meeting
      • Governance
        • Corporate Governance
        • Management Team
      • Resources
        • Investor Email Alerts
    • Media
      • Media Hub
      • All Press Releases
      • Media Center
    • Careers
Download item year list
Date Download Description
May 18, 2016
Report and termination of the liquidity contract with Gilbert Dupont (opens in new window)
9 KB
January 5, 2016
Full-year report on Innate Pharma's liquidity contract with Gilbert Dupont (opens in new window)
9 KB
July 2, 2015
2015 Half-year report on Innate Pharma’s liquidity contract with Gilbert Dupont (opens in new window)
9 KB
January 8, 2015
Full-year report on Innate Pharma’s liquidity contract with Gilbert Dupont (opens in new window)
8 KB

Investor Relations Contact

Henry Wheeler
Vice-President, Investor Relations & Communications

Investors@innate-pharma.fr


Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Innate Pharma, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Innate Pharma to send you the requested Investor Email Alert updates.

* Required

*
Investor Alert Options
*





Unsubscribe Désabonnement

Email Alert Sign Up Confirmation

  • Contact
  • Location
  • Legal Info
  • Terms of use
  • Privacy Notice
  • Cookie Notice

Follow us

Twitter   LinkedIn  

Stay in touch

Subscribe to our newsletter  Subscribe to our newsletter

Contact us form  Contact us
 

Location

Company Address France 117, Avenue de Luminy - BP 30191
13 009 Marseille FRANCE

Company Phone Number  +33 (0)4 30 30 30 30

Comapny Address USA  Innate Pharma, Inc.
2273 Research Boulevard, Suite 350
Rockville, MD 20850, USA

Innate Pharma logo
Powered By Q4 Inc. 5.134.1.1 (opens in new window)